NASDAQ:CORT 16 December 2025

Corcept Therapeutics (NASDAQ:CORT) surges 27% after Lifyorli boosts second-half expectations

Shares of Corcept Therapeutics Incorporated jumped 27.4% to $118.41 as of 13:45 EDT. The company reported a 32% increase in quarterly sales and lifted its full-year guidance.

30 July 2026

Earnings·NASDAQ:CORT·NASDAQ:XERS·Pharmaceuticals·Stock Market

Corcept Therapeutics (CORT) stock rebounds today after FDA setback — here’s what investors are watching next

Corcept Therapeutics Incorporated shares were up 5.7% at $36.77 on Friday afternoon, after a sharp selloff earlier in the week tied to a U.S. regulatory setback for its experimental drug relacorilant.

2 January 2026

NASDAQ:CORT·Pharmaceuticals·Stock Market

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

Vanda Pharmaceuticals’ FDA win in motion sickness set the tone for outsized, stock-specific swings in healthcare shares as Wall Street paused for the New Year’s Day holiday. U.S. stock markets were closed Thursday. Nasdaq

1 January 2026

NASDAQ:AXSM·NASDAQ:CORT·NASDAQ:VNDA

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics Inc shares last ended Wednesday down 50.4% at $34.80 after the company said U.S. regulators were not ready to approve its drug relacorilant for a form of high blood pressure linked to hypercortisolism. U.S. stock markets are shut on Thursday for New Year’s Day. HCPLive

1 January 2026

NASDAQ:CORT·Pharmaceutical Industry·Stock Market

Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics Incorporated shares last closed down 50.4% at $34.80 on Wednesday. Yahoo Finance

1 January 2026

NASDAQ:CORT·Pharmaceuticals·Stock Market

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept Therapeutics Inc shares sank about 50% in after-hours trading on Wednesday after the U.S. Food and Drug Administration declined to approve its oral drug relacorilant for a Cushing’s-related hypertension use. The stock was last at $34.80, down $35.39 from the prior close. Reuters

1 January 2026

NASDAQ:CORT·Pharmaceutical Industry·Stock Market

Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Shares of Corcept Therapeutics Incorporated sank nearly 50% on Wednesday after the U.S. Food and Drug Administration issued a complete response letter for the company’s relacorilant application in hypertension secondary to hypercortisolism, also known as Cushing’s syndrome. The stock was down 49.7% at $35.31 in afternoon trading. Nasdaq

31 December 2025

NASDAQ:CORT·Pharmaceuticals·Stock Market

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept Therapeutics Inc shares fell 8.9% to $72.72 in early afternoon Nasdaq trading on Tuesday, after touching a session low of $72.26. The stock was last down $7.10 from Monday’s close, with about 897,000 shares traded.

30 December 2025

NASDAQ:CORT·Pharmaceutical Industry·Stock Market

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

Corcept Therapeutics Incorporated ended Tuesday, December 16, 2025, sharply lower after a strong 2025 run that had pushed expectations—and valuation—into the spotlight. Shares closed at $79.44, down $7.86 from the prior close, after trading as low as $78.84 on the day.

16 December 2025

Biotechnology·NASDAQ:CORT·Pharmaceutical Industry·Stock Market

NASDAQ:CORT 16 December 2025 - 30 July 2026

Corcept Therapeutics (NASDAQ:CORT) surges 27% after Lifyorli boosts second-half expectations

Corcept Therapeutics (CORT) stock rebounds today after FDA setback — here’s what investors are watching next

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept Therapeutics (CORT) Stock Drops on Dec. 16, 2025: UBS Neutral Call, Relacorilant FDA Catalyst, and Updated Price Targets

TechStock² Updates

Atlassian (NASDAQ:TEAM) Jumps 35% as Cloud Growth Outruns Its 13% Outlook

Barrick Mining (NYSE:B) heads for North America IPO challenge following 19% weekly surge

Tesla (NASDAQ:TSLA) Rises 5.6% on Surge in Retail Interest, Marginally Outperforming Nasdaq

Applied Materials (NASDAQ:AMAT) Weekly Gain Highlights Cash Conversion After Earnings

TeraWulf Shares Face 12% Hurdle With 839-MW AI Pipeline as U.S. Markets Close

Top Stock Picks

AerCap

Constellation Energy

Cheniere Energy

Walt Disney

AIG

Live updates

Investment Disclaimer